BuzzSparks.org

SR One


Venture Capital

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested...

Founded in 1985
Homepage:

HQ

02142 One Broadway

Cambridge
Cambridge
USA MA

Phone: 610.567.1000

Updated on Jun 15, 2009
SR One at CrunchBase
Kent Gossett Partner
Rajeev Dadoo Partner
Matthew Foy Partner
Simeon J. George Partner
Deborah Harland Partner
David Phillips Partner
Jill carroll Sr Associate
Jens Eckstein President
Brian Gallagher Partner
Vikas Goyal Sr. Associate
Karen Narolewski Engel Finance Manager
Past
Elaine Jones VP
Russell Greig President, SR One
Deborah Harland General Partner
Carol Ashe Partner
Todd Holmes Summer Associate

September, 2013

SR One invested $30M in iPierian as a Series A round

July, 2013

SR One invested $60M in Dicerna Pharmaceuticals as a Series C round

May, 2013

SR One invested $45M in Effector Therapeutics as a Series A round

January, 2013

SR One invested $12M in Aileron Therapeutic as a Series D round

December, 2012

SR One invested $17M in River Vision Development as a Series A round

SR One invested $5.9M in Bicycle Therapeutics as unattributed round

November, 2012

SR One invested $37.5M in Applied Genetics Technologies Corporation as a Series B round

October, 2012

SR One invested $12.5M in Principia BioPharma as a Series A round

SR One invested $35M in Thrasos as a Series C round

SR One invested $30M in Genocea Biosciences as a Series C round

September, 2012

SR One invested $28M in IlluminOss Medical as a Series C round

June, 2012

SR One invested $18M in Auxogyn as a Series B round

January, 2012

SR One invested $20.7M in RaNA Therapeutics as a Series A round

August, 2011

SR One invested $10M in MISSION Therapeutics as unattributed round

June, 2011

SR One invested $24M in Nimbus Discovery as a Series A round

SR One invested $500K in HTG Molecular Diagnostics as a Series D round

SR One invested $15M in Constellation Pharmaceuticals as a Series B round

May, 2011

SR One invested $15M in Springleaf Therapeutics as a Series B round

April, 2011

SR One invested $20.3M in f-star Biotech as unattributed round

January, 2011

SR One invested $35M in Genocea Biosciences as a Series B round

December, 2010

SR One invested $18M in Semprus BioSciences as a Series B round

November, 2010

SR One invested $29M in Syntaxin as a Series C round

October, 2010

SR One invested $4M in Dicerna Pharmaceuticals as a Series B round

September, 2010

SR One invested $28M in iPierian as a Series B round

June, 2010

SR One invested $4.8M in Constellation Pharmaceuticals as a Series B round

May, 2010

SR One invested $43M in NeuroTherapeutics Pharma as a Series B round

December, 2009

SR One invested $12M in CalciMedica as a Series C round

November, 2009

SR One invested $7.5M in Trinity Biosystems as unattributed round

June, 2009

SR One invested $40M in Aileron Therapeutic as a Series D round

SR One invested $13M in Anaphore as a Series A round

January, 2009

SR One invested $25M in Rib-X Pharmaceuticals as unattributed round

SR One invested $4M in CalciMedica as a Series C round

January, 2008

SR One invested $25M in POINT Biomedical as a Series E round

October, 2007

SR One invested $32M in Syntaxin as a Series B round

July, 2007

SR One invested $1.5M in CalciMedica as a Series A round

May, 2006

SR One invested $12.7M in Onyvax as a Series C round

1985

SR One was founded in 1985